ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 2630 • 2019 ACR/ARP Annual Meeting

    A Dutch Consensus Statement on the Diagnosis and Treatment of ANCA Associated Vasculitis

    Ebru Dirikgil1, Peter Verhoeven 2, Sander Tas 3, Abraham Rutgers 4, Hein Bernelot Moens 5, Jacob van Laar 6, Willem Jan Bos 7 and Onno Teng 1, 1LUMC, Leiden, Netherlands, 2The Dutch Vasculitis Foundation, Silvolde, Netherlands, 3Amsterdam Rheumatology & immunology Center, Amsterdam UMC/University of Amsterdam, Amsterdam, Netherlands, 4University Medical Center Groningen, Groningen, Netherlands, 5Ziekenhuisgroep Twente, Almelo, Netherlands, 6UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, 7St. Antoniusziekenhuis, Nieuwegein, Netherlands

    Background/Purpose: Several guidelines have been published on the diagnosis and treatment of anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV). These guidelines provide an evidence-based approach…
  • Abstract Number: 810 • 2019 ACR/ARP Annual Meeting

    Small Vessel Vasculitis Syndrome with Autoinflammation Caused by De Novo Mutations in LYN Kinase

    Adriana de Jesus1, Gina Montealegre Sanchez 2, Helen Freeman 3, Neil Martin 4, Ebun Omoyinmi 5, Katherine Calvo 6, Richard Chyi-chia Lee 7, Murray Passo 8, Natasha Ruth 8, David Kleiner 7, Yan Huang 9, Nirali Shah 10, Paul Brogan 11, SuJin Hwang 12, HyeSun Kuehn 12, Sergio Rosenzweig 12, Zuoming Deng 13, Anna Huttenlocher 14, Susan Moir 15, Douglas Kuhns 16 and Raphaela Goldbach-Mansky 17, 1Translation Autoinflammatory Diseases Section/NIAID/NIH, Silver Spring, MD, 2Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, 3Raigmore Hospital, Inverness, United Kingdom, 4Royal Hospital for Children, Glasgow, United Kingdom, 5University College London Institute of Child Health, London, United Kingdom, 6Hematology Service/Department of Laboratory Medicine/NIH, Bethesda, MD, 7Laboratory of Pathology/NCI/NIH, Bethesda, MD, 8Medical University of South Carolina, Charleston, SC, 9Translational Autoinflammatory Disease Section/NIAID/NIH, Bethesda, MD, 10Pediatric Oncology Branch/NCI/NIH, Bethesda, MD, 11Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom, 12Immunology Service/Department of Laboratory Medicine/NIH, Bethesda, MD, 13Biomining and Discovery Section/NIAMS/NIH, Bethesda, MD, 14Department of Pediatrics/University of Wisconsin, Madison, WI, 15Immunopathogenesis Section/NIAID/NIH, Bethesda, MD, 16Collaborative Clinical Research Branch/NIAID/NIH, Bethesda, MD, 17Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, MD

    Background/Purpose: Lyn kinase is a member of the Src family of non-receptor tyrosine-protein kinases that modifies signals from various cell surface receptors and regulates innate…
  • Abstract Number: 1681 • 2019 ACR/ARP Annual Meeting

    The Association of Reduced Low-Density Lipoprotein (LDL) Cholesterol Levels with ANCA-Associated Vasculitis (AAV)

    Zachary Wallace1, Xiaoqing Fu 1, Yuqing Zhang 2, John Stone 3 and Hyon K. Choi 2, 1Massachusetts General Hospital, Boston, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

    Background/Purpose: ANCA-associated vasculitis (AAV) is a small vessel vasculitis associated with an intense inflammatory state.  AAV patients are at a 2-fold higher risk of cardiovascular…
  • Abstract Number: 2632 • 2019 ACR/ARP Annual Meeting

    Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center

    Sana Afroz1 and Najia Shakoor 2, 1RUMC, Chicago, IL, 2Rush University Medical Center, Chicago, IL

    Background/Purpose: For years, cyclophosphamide (CYC) has been the primary treatment for severe anca-associated vasculitides (AAV) and has significantly improved disease related mortality.  In addition, maintenance…
  • Abstract Number: 869 • 2019 ACR/ARP Annual Meeting

    Clinical Manifestations of Patients with Eosinophilic Granulomatosis with Polyangiitis in a Large North American Cohort

    Irena Doubelt1, David Cuthbertson 2, Simon Carette 1, Nader A. Khalidi 3, Curry L. Koening 4, Carol Langford 5, Carol A. McAlear 6, Larry W. Moreland 7, Paul Monach 8, Philip Seo 9, Ulrich Specks 10, Antoine Sreih 11, Steven Ytterberg 10, Peter A. Merkel 12, Christian Pagnoux 1 and VCRC Vasculitis Clinical Research Consortium 13, 1Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 2University of South Florida, Tampa, FL, 3McMaster University, Hamilton, ON, Canada, 4University of Utah Hospital, Salt Lake City, UT, 5Cleveland Clinic, Cleveland, OH, 6University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, 7University of Pittsburgh, Pittsburgh, PA, 8Brigham and Women's Hospital, Boston, MA, 9Johns Hopkins Medicine, Baltimore, MD, 10Mayo Clinic College of Medicine, Rochester, MN, 11University of Pennsylvania, Philadelphia, PA, 12Univeristy of Pennsylvania, Philadelphia, PA, 13University of Pennsylvania, Division of Rheumatology, philadelphia

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, systemic necrotizing small-vessel vasculitis, with only a few published North American series. This project aimed to…
  • Abstract Number: 1687 • 2019 ACR/ARP Annual Meeting

    Dramatic but Suspensive Effect of interleukin-1 Inhibitors on Persistent Urticarial Vasculitis

    Thomas Bettuzzi 1, Alban Deroux 2, Marie Jachiet 3, Meryem-Maud Farhat 4, Julien Wipff 1, Marc Fabre 5, Laurence Bouillet 2, Nora Kramkimel 1, Selim Aractingi 1, Nicolas Dupin 1 and Benjamin Terrier6, 1Cochin Hospital, Paris, France, 2CHU, Grenoble, France, 3Saint Louis Hospital, Paris, France, 4CHRU, Lille, France, 5CH, Bourgoin-Jailleu, France, 6National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France

    Background/Purpose: Urticarial vasculitis (UV) is a rare disease characterized by dermal capillary inflammation responsible for long-lasting urticarial lesions. UV can be separated into 2 different…
  • Abstract Number: 2634 • 2019 ACR/ARP Annual Meeting

    ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients

    Laura van Dam1, Ebru Dirikgil 2, Edwin Bredewold 2, Argho Ray 2, Ton Rabelink 2, Cees van Kooten 2 and Onno Teng 2, 1LUMC, Leiden, Zuid-Holland, Netherlands, 2LUMC, Leiden, Netherlands

    Background/Purpose: Recent studies have demonstrated that in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) with successful remission-induction (RI) after cyclophosphamide (CYC), maintenance treatment with…
  • Abstract Number: 871 • 2019 ACR/ARP Annual Meeting

    ANCA-Associated Vasculitis Management in the United States: Data from the RISE Registry

    Zachary Wallace1, Huifeng Yun 2, Jeffrey Curtis 2, Shuo Yang 2, Lang Chen 2, John Stone 3 and Hyon K. Choi 4, 1Massachusetts General Hospital, Boston, 2University of Alabama at Birmingham, Birmingham, AL, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Boston, MA

    Background/Purpose: The management of ANCA-associated vasculitis (AAV) evolved substantially in recent years because of evidence supporting the efficacy of various treatment regimens.  As such, treatment…
  • Abstract Number: 1688 • 2019 ACR/ARP Annual Meeting

    Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial

    Benjamin Terrier1, Jonathan London 2, Fabrice Bonnet 3, Diane Cerutti 4, Nathalie Costedoat-Chalumeau 5, Elisabeth Diot 6, Yasmina Ferfar 7, Aurélie Hummel 8, Gilles Kaplanski 9, Isabelle Marie 10, Thomas Quémeneur 11, Patricia Rullier 12, Patricia Senet 13, Noémie Le Gouellec 14, Julie Lejeune 7, David Saadoun 15 and Patrice Cacoub 15, 1National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, 2Croix Saint-Simon Hospital, Paris, France, 3CHU, Bordeaux, France, 4CH, Toulon, France, 5Cochin University Hospital, Paris, France, 6APHP, Tours, France, 7Pitié-Salpétrière Hospital, Paris, France, 8APHP, Paris, France, 9CHU, Marseille, France, 10CHU, Rouen, France, 11CH Valenciennes, Valenciennes, France, 12CHU, Montpellier, France, 13Tenon Hospital, Paris, France, 14CH, Valenciennes, France, 15AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France

    Background/Purpose: A previous retrospective study suggested superiority of glucocorticoids (GCs) plus rituximab (RTX) compared to GCs alone to induce complete clinical response in non-infectious cryoglobulinemia…
  • Abstract Number: 2635 • 2019 ACR/ARP Annual Meeting

    Accuracy of Self-Reported Diagnosis of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

    Tanaz Kermani1, Jason Springer 2, Antoine Sreih 3, Dianne Shaw 4, Kalen Young 5, Cristina Burroughs 6 and Peter Merkel 3, 1University of California Los Angeles, Los Angeles, CA, 2Kansas University Medical Center, Kansas, MO, 3University of Pennsylvania, Philadelphia, PA, 4Vasculitis Foundation, North Carolina, 5Vasculitis Foundation, Kansas City, MO, 6University of South Florida, Tampa, FL

    Background/Purpose: To determine the reliability of self-reported diagnosis of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with…
  • Abstract Number: 873 • 2019 ACR/ARP Annual Meeting

    Survival After Lung Transplantation in Adults with Primary Systemic Vasculitides: Analysis of the United Network of Organ Sharing (UNOS) Database

    Sebastian E. Sattui1, Zafir Abutalib 2, Jackie Finik 2 and Robert Spiera 3, 1Hospital for Special Surgery, New York, 2Hospital for Special Surgery, New York, NY, New York, NY, 3Hospital for Special Surgery, New York, NY

    Background/Purpose: Pulmonary involvement, including pulmonary vascular disease and interstitial lung disease can be an important cause of morbidity and even mortality in patients with primary…
  • Abstract Number: 1704 • 2019 ACR/ARP Annual Meeting

    Efficacy of Leflunomide for Treatment of Vasculitis

    NOURA MUSTAPHA 1, Lillian Barra 2, Simon Carette 3, David Cuthbertson 4, Nader A. Khalidi 5, Curry L. Koening 6, Carol Langford 7, Carol McAlear 8, Nataliya Milman 9, Larry Moreland 10, Paul Monach 11, Philip Seo 12, Ulrich Specks 13, Antoine Sreih 14, Steven Ytterberg 13, Peter Merkel 14, Christian Pagnoux15, CanVasc Canadian Vasculitis Research Network 16 and VCRC Vasculitis Clinical Research Consortium 8, 1Hopital Notre Dame, Montreal, QC, Canada, 2St Joseph's health care, London, Canada, 3Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, 4University of South Florida, Tampa, FL, 5McMaster University, Hamilton, ON, Canada, 6University of Utah Hospital, Salt Lake City, UT, 7Cleveland Clinic, Cleveland, OH, 8University of Pennsylvania, Division of Rheumatology, Philadelphia, 9Arthritis Centre at the Ottawa Hospital, Riverside Campus, Ottawa, Canada, 10University of Pittsburgh, PITTSBURGH, PA, 11Brigham and Women's Hospital, Boston, MA, 12Johns Hopkins Medicine, Baltimore, MD, 13Mayo Clinic College of Medicine, Rochester, MN, 14University of Pennsylvania, Philadelphia, PA, 15Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 16Mount Sinai Hospital, Vasculitis clinic, toronto, ON, Canada

    Background/Purpose: Only a few small case series, case reports, and one small clinical trial suggested some benefit of leflunomide (LEF) in ANCA-associated vasculitis and other…
  • Abstract Number: 2638 • 2019 ACR/ARP Annual Meeting

    The Cumulative Burden of Damage for Patients with Eosinophilic Granulomatosis with Polyangiitis

    Irena Doubelt1, David Cuthbertson 2, Gunnar Tomasson 3, Simon Carette 1, Nader A. Khalidi 4, Curry L. Koening 5, Carol Langford 6, Carol A. McAlear 7, Larry W. Moreland 8, Paul Monach 9, Philip Seo 10, Ulrich Specks 11, Antoine Sreih 12, Kalen Young 13, Steven Ytterberg 11, Peter A. Merkel 14, Christian Pagnoux 1 and VCRC Vasculitis Clinical Research Consortium 15, 1Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 2University of South Florida, Tampa, FL, 3Faculty of Medicine, University of Iceland and Landpitali University Hospital, Reykjavik, Iceland, 4McMaster University, Hamilton, ON, Canada, 5University of Utah Hospital, Salt Lake City, UT, 6Cleveland Clinic, Cleveland, OH, 7University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, 8University of Pittsburgh, Pittsburgh, PA, 9Brigham and Women's Hospital, Boston, MA, 10Johns Hopkins Medicine, Baltimore, MD, 11Mayo Clinic College of Medicine, Rochester, MN, 12University of Pennsylvania, Philadelphia, PA, 13Vasculitis Foundation, Kansas City, MO, 14Univeristy of Pennsylvania, Philadelphia, PA, 15University of Pennsylvania, Division of Rheumatology, philadelphia

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by asthma and other manifestations of vasculitis, some of which can be life-threatening, cause major organ damage,…
  • Abstract Number: 966 • 2019 ACR/ARP Annual Meeting

    Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients

    Laura van Dam1, Jelle Oskam 2, Sylvia Kamerling 2, Eline Arends 2, Edwin Bredewold 2, Magda Berkowska 2, Jacques van Dongen 2, Ton Rabelink 2, Cees van Kooten 2 and Onno Teng 2, 1LUMC, Leiden, Zuid-Holland, Netherlands, 2LUMC, Leiden, Netherlands

    Background/Purpose: Background: B-cell depletion with rituximab (RTX) is an effective treatment for ANCA-associated vasculitis (AAV) patients. Repeated RTX upon B-cell repopulation or return of ANCAs…
  • Abstract Number: 1712 • 2019 ACR/ARP Annual Meeting

    Head and Neck Involvement of IgA Vasculitis: A Case-Control Study

    Michel Villatoro-Villar1, David Wetter 1, Cynthia Crowson 2, Kenneth Warrington 1 and Matthew Koster 1, 1Mayo Clinic Rochester, Rochester, MN, 2Mayo Clinic Rochester, Rochester

    Background/Purpose: IgA vasculitis (IgAV) is an immune-complex mediated, small-vessel vasculitis which predominantly involves the skin on the lower extremities. Head and neck involvement is rarely…
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology